160 related articles for article (PubMed ID: 36752579)
21. Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.
Rigo R; Ding PQ; Batuyong E; Cheung WY; Walker J; Monzon JG; Cheng T
Oncologist; 2024 Jan; 29(1):57-66. PubMed ID: 37648247
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
23. Adjuvant treatment for melanoma in clinical practice - Trial versus reality.
de Meza MM; Ismail RK; Rauwerdink D; van Not OJ; van Breeschoten J; Blokx WAM; de Boer A; van Dartel M; Hilarius DL; Ellebaek E; Bonenkamp HJ; Blank CU; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JWB; Haanen JB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil A; Westgeest HM; van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
Eur J Cancer; 2021 Nov; 158():234-245. PubMed ID: 34600790
[TBL] [Abstract][Full Text] [Related]
24. Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma.
Mo Z; Liu J; Zhang J; Deng Y; Xu M; Jiang Y
Int Immunopharmacol; 2023 Nov; 124(Pt B):110973. PubMed ID: 37769536
[TBL] [Abstract][Full Text] [Related]
25. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA; Di Giacomo AM; Chiarion Sileni V; Queirolo P; Spagnolo F; De Galitiis F; Cognetti F; Mandalà M; Guidoboni M; Rinaldi G; Depenni R; Consoli F; Troiani T; Guida M; Marconcini R; Ferrucci PF; Strippoli S; Fava P; Merelli B; Simeone E; Di Guardo L; Giannarelli D; Maio M; Quaglino P; Del Vecchio M
Eur J Cancer; 2023 Sep; 191():113246. PubMed ID: 37549531
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
27. Novel adjuvant options for cutaneous melanoma.
Dimitriou F; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
[TBL] [Abstract][Full Text] [Related]
28. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Gibney GT; Kudchadkar RR; DeConti RC; Thebeau MS; Czupryn MP; Tetteh L; Eysmans C; Richards A; Schell MJ; Fisher KJ; Horak CE; Inzunza HD; Yu B; Martinez AJ; Younos I; Weber JS
Clin Cancer Res; 2015 Feb; 21(4):712-20. PubMed ID: 25524312
[TBL] [Abstract][Full Text] [Related]
29. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
31. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Eckardt J; Schroeder C; Martus P; Armeanu-Ebinger S; Kelemen O; Gschwind A; Bonzheim I; Eigentler T; Amaral T; Ossowski S; Rieß O; Flatz L; Garbe C; Forschner A
J Cancer Res Clin Oncol; 2023 Feb; 149(2):833-840. PubMed ID: 35192052
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber JS; Schadendorf D; Del Vecchio M; Larkin J; Atkinson V; Schenker M; Pigozzo J; Gogas H; Dalle S; Meyer N; Ascierto PA; Sandhu S; Eigentler T; Gutzmer R; Hassel JC; Robert C; Carlino MS; Di Giacomo AM; Butler MO; Muñoz-Couselo E; Brown MP; Rutkowski P; Haydon A; Grob JJ; Schachter J; Queirolo P; de la Cruz-Merino L; van der Westhuizen A; Menzies AM; Re S; Bas T; de Pril V; Braverman J; Tenney DJ; Tang H; Long GV
J Clin Oncol; 2023 Jan; 41(3):517-527. PubMed ID: 36162037
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA;
Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502
[TBL] [Abstract][Full Text] [Related]
34. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
Owen CN; Shoushtari AN; Chauhan D; Palmieri DJ; Lee B; Rohaan MW; Mangana J; Atkinson V; Zaman F; Young A; Hoeller C; Hersey P; Dummer R; Khattak MA; Millward M; Patel SP; Haydon A; Johnson DB; Lo S; Blank CU; Sandhu S; Carlino MS; Larkin JMG; Menzies AM; Long GV
Ann Oncol; 2020 Aug; 31(8):1075-1082. PubMed ID: 32387454
[TBL] [Abstract][Full Text] [Related]
35. Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL.
Rogiers A; Willemot L; McDonald L; Van Campenhout H; Berchem G; Jacobs C; Blockx N; Rorive A; Neyns B
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835517
[TBL] [Abstract][Full Text] [Related]
36. Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland.
Staeger R; Martínez-Gómez JM; Turko P; Ramelyte E; Kraehenbuehl L; Del Prete V; Hasan Ali O; Levesque MP; Dummer R; Nägeli MC; Mangana J
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473216
[TBL] [Abstract][Full Text] [Related]
37. Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or
Placzke J; Rosińska M; Sobczuk P; Ziętek M; Kempa-Kamińska N; Cybulska-Stopa B; Kamińska-Winciorek G; Bal W; Mackiewicz J; Galus Ł; Las-Jankowska M; Jankowski M; Dziura R; Drucis K; Borkowska A; Świtaj T; Rogala P; Kozak K; Klimczak A; Jagodzińska-Mucha P; Szumera-Ciećkiewicz A; Koseła-Paterczyk H; Rutkowski P
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686659
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
[TBL] [Abstract][Full Text] [Related]
39. Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
Stahlie EHA; Zijlker LP; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
Melanoma Res; 2024 Feb; 34(1):63-69. PubMed ID: 38016153
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]